Find Academic Supervisors

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +12 more

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

Jacques ArchambaultView profile

Professor

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +4 more

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

Brent PageView profile

Associate Professor

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +13 more

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

Eric W. SchmidtView profile

Professor

• Natural Products Chemistry
• Biosynthesis
• Synthetic Biology
• +5 more

Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition

Kibret MequanintView profile

Professor

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +6 more

Dr. Kibret Mequanint is a full Professor at Western University's Department of Chemical and Biochemical Engineering, with cross-appointments in Biomedical Engineering. Holding a PhD from University of Stellenbosch and postdoctoral experience at Technical University of Darmstadt and McMaster University, his research bridges polymer science, materials engineering, and life sciences with applications in Biomaterials , Tissue Engineering , and Regenerative Medicine . His work spans both fundamental and translational research in cell-material interactions , polymer biomaterial design , and therapeutic radiation dosimeters , with technologies transferred to commercial applications. Leading scholar and educator with awards from NSERC, CIHR, and Western University Fellow of: American Institute for Medical and Biological Engineering (AIMBE), Ethiopian Academy of Sciences, International Union of Societies for Biomaterials Science and Engineering, Canadian Academy of Engineering Extensive editorial and panel service for NSERC, CIHR, and international journals His research program has produced over 170 refereed publications, focusing on conductive hydrogels , bioadhesives , and vascular tissue engineering . Recent work on endoscopy-deliverable bioadhesives and snake venom-derived hemostatic gels has attracted global media attention. He has served in leadership roles at the Canadian Biomaterials Society and university governance bodies including Senate and Board of Governors.

Gerrit Jan PoelarendsView profile

Professor

• Biocatalysis
• Enzymology
• Protein engineering
• +8 more

Professor Gerrit Jan Poelarends is a distinguished academic at the University of Groningen, holding the position of Professor of Pharmaceutical Biotechnology within the Faculty of Science and Engineering. He serves as Director of the Groningen Research Institute of Pharmacy and Head of the Department of Chemical and Pharmaceutical Biology. His extensive research portfolio spans biocatalysis, enzyme engineering, and sustainable pharmaceutical synthesis, with significant contributions to the UN Sustainable Development Goals through environmentally friendly chemical processes. Prof. Poelarends' research interests focus on the discovery and design of novel biocatalysts for pharmaceutical applications. His work centers on developing enzymatic pathways for asymmetric synthesis of noncanonical amino acids, creating enantioselective biocatalysts for various synthetic bond-forming methodologies, and characterizing promiscuous protein functions to understand enzyme evolution. His research group actively explores enzyme engineering guided by mutability landscapes, development of engineered peroxygenases, and discovery of ene- and nitroreductases for sustainable chemistry applications. Analysis of his recent publications reveals a strong trend toward sustainable pharmaceutical synthesis through enzyme engineering, particularly in the areas of nitroreductases, C-N lyases, and peroxygenases. His work consistently bridges fundamental enzymology with practical applications in green chemistry, demonstrating expertise in both understanding enzyme evolution and applying this knowledge to create biocatalysts for environmentally friendly production of pharmaceuticals. His scientific achievements have been recognized through numerous prestigious awards including NWO VENI, VIDI, and VICI grants, ERC Starting and Proof of Concept grants, and competitive fellowships for his students. These awards highlight the innovative nature and impact of his research in biocatalysis and enzyme engineering. Prof. Poelarends has supervised over thirty PhD students throughout his career, with current supervision of multiple doctoral candidates working on projects related to enzyme engineering and biocatalysis. His research has been supported by substantial grants from NWO, the European Union (including multiple ERC grants), and collaborative international projects, reflecting the significance and scope of his work. The Pharmaceutical Biotechnology group he leads includes technicians, postdocs, and PhD students working on various aspects of enzyme discovery and engineering. The research team operates within well-established laboratory facilities at the Groningen Research Institute of Pharmacy, with access to state-of-the-art equipment for protein expression, purification, structural analysis, and biocatalytic reaction screening. Their work is closely integrated with the University of Groningen's broader research initiatives in sustainable chemistry and pharmaceutical sciences, contributing to multiple EU-funded training networks and collaborative projects.

Adrian WhittyView profile

Associate Professor

• Biochemistry
• Structural Biology
• Drug Discovery
• +3 more

Adrian Whitty is an Associate Professor in the Department of Biology at Boston University . His research focuses on protein-protein and protein-ligand recognition, particularly in developing mechanistic understandings of growth factor receptor activation and advancing drug discovery for protein-protein interaction inhibition. Education: B.Sc. (Honors) in Chemistry from King’s College, University of London (1985); Ph.D. in Organic Chemistry from the University of Illinois at Chicago (1991); Postdoctoral Research Fellow at Brandeis University's Biochemistry Department (1990-93). His work integrates biochemical and cell-based assays using advanced technologies like FRET, Time-Resolved Fluorescence, and Surface Plasmon Resonance (Biacore 3000). He collaborates with computational chemists, organic synthesis experts, X-ray crystallographers, and biologists to develop novel approaches for designing small molecule inhibitors of protein-protein interactions. Recent publications highlight trends in machine learning applications for molecular scientists, structural analysis of enzyme mechanisms, macrocycle-based drug design, and quantitative studies of protein interaction energetics. His lab emphasizes rigorous hypothesis-driven experimental design, preparing students for careers in academia or industry. Advisory and leadership roles include membership in The Protein Society (2008-present), the American Society of Biochemistry and Molecular Biology (ASBMB) Governing Council (2007-present), and founding roles in the Council for Systems Biology in Boston (CSB2) and the Institute for Chemical Biology and Drug Discovery at SUNY Stony Brook. His laboratory is equipped with state-of-the-art facilities for fluorescence, analytical ultracentrifugation (AUC), dynamic light scattering (DLS), isothermal titration calorimetry (ITC), and tissue culture, supporting diverse techniques including flow cytometry and reaction pathway modeling with Mathematica and MATLAB.

• Cardiovascular Research
• Structural Biology
• Drug Design
• +7 more

Professor Alexander Breeze is a Chair in the School of Medicine at the University of Leeds, affiliated with the Multidisciplinary Cardiovascular Research Centre. His research focuses on structural biology, drug design, and molecular mechanisms of disease, particularly involving protein-protein interactions and NMR spectroscopy. Key areas include RAS oncogene inhibition, fibroblast growth factor receptors (FGFRs), and amyloid aggregation modulation. Education Background: Details of formal education not explicitly provided in the text, but extensive career history in structural biology and medicinal chemistry suggests advanced degrees in relevant fields. Research Interests: Professor Breeze’s work spans cardiovascular research, cancer biology, and infectious diseases. He develops novel therapeutics targeting oncogenic signaling pathways (e.g., RAS, FGFR) and investigates mechanisms of protein misfolding in amyloid diseases. His lab employs fragment-based drug design, NMR spectroscopy, and computational methods to study protein dynamics and drug interactions. Publications Overview: His recent work highlights advancements in small-molecule inhibitors for RAS proteins, CRACR2A genetic associations with COVID-19 severity, and modulation of amyloid aggregation pathways. Research trends emphasize translational applications, bridging basic science and clinical targets like cancer and neurodegenerative diseases. Awards & Recognition: No specific awards mentioned in the provided text, though his sustained high-impact publications suggest recognition in the field. Grants & Advising: Leadership in multidisciplinary cardiovascular research and training of early-career researchers through collaborative projects. No explicit grant details provided in this dataset. Labs & Teams: Active in the Multidisciplinary Cardiovascular Research Centre, fostering cross-departmental collaborations in cardiovascular and structural biology research.

Jens CarlssonView profile

Professor

• G protein-coupled receptors (GPCRs)
• Structure-based drug design
• Molecular docking
• +7 more

Jens Carlsson is a Professor at Uppsala University, affiliated with the Department of Cell and Molecular Biology and the Science for Life Laboratory (SciLifeLab) . His research focuses on computational biochemistry , particularly G protein-coupled receptors (GPCRs) , using physics-based modeling to advance structure-based drug design . Academic rank: Full Professor (since 2022) Key methodologies: Molecular dynamics simulations, docking, free energy calculations Research themes: GPCR ligand interactions, virtual chemical space screening, allosteric modulators Recent work (2025) highlights AI-driven discovery of brain disease therapeutics and DNA repair inhibitors , while 2024 projects explore AlphaFold applications in TAAR1 agonist design . His group has received Swedish Research Council grants (3.6M SEK, 6M SEK) and industry collaborations . Scientific awards include the Göran Gustafsson Prize (2016), Excellence Prize in Molecular Design (2022), and Ingvar Carlsson Award (2012). Key students include PhD candidates Mariama Jaiteh and Pierre Matricon , with postdocs like Nicolas Panel and Duy Duc Vo .

Gaetano MontelioneView profile

Professor

• Protein Structure and Dynamics
• NMR Spectroscopy
• Structural Bioinformatics
• +6 more

Gaetano Montelione is a Professor and Constellation Endowed Chair in the Department of Chemistry and Chemical Biology at Rensselaer Polytechnic Institute (RPI), directing the Center for Biotechnology and Interdisciplinary Studies (CBIS). His laboratory pioneers NMR methodology development for protein structure and dynamics analysis, with extensive expertise in high-throughput structural genomics from leading the NIGMS-funded Northeast Structural Genomics Consortium (NESG) for 16 years. His research spans Protein Structure and Dynamics , NMR Spectroscopy , and Structural Bioinformatics , with critical applications in Membrane Proteins , Virology , and Drug Design . The lab integrates X-ray crystallography, SAXS, and computational modeling to tackle challenging targets like integral membrane proteins and viral systems, emphasizing hybrid approaches where sparse experimental data guides AI-driven structure prediction. Analysis of 2024-2025 publications reveals dominant trends in AI-structural biology integration, particularly AlphaFold2 applications for membrane proteins and protein complexes. Virology research focuses intensely on SARS-CoV-2 protease inhibitors and host-pathogen interactions, while de novo protein design and structural validation methods drive innovation in therapeutic development and fundamental biophysics. The Montelione Laboratory maintains a global collaborative network with experts in evolutionary coupling (Sander, Marks), Rosetta modeling (Baker), and biophysical methods (Luchinat, Tainer). As a central node in structural biology consortia like CASP and wwPDB, the lab develops rigorous quality assessment frameworks while advancing biomedical projects on influenza, DNA repair, and cancer biology through partnerships with Rutgers, Mt. Sinai, and international institutions.

Xavier DarzacqView profile

Professor

• Transcription Regulation
• Nuclear Organization
• Cellular Differentiation
• +6 more

Xavier Darzacq is a Professor of Molecular Therapeutics at the University of California, Berkeley, holding the Edward E. Penhoet Distinguished Endowed Chair in Global Health and Infectious Disease. His research at the intersection of molecular biology and biophysics focuses on understanding how nuclear organization governs transcription regulation during cellular differentiation. Research Highlights: Investigates transcriptional control via non-canonical mediator complexes in fibroblast-to-myofibroblast differentiation. Develops advanced imaging techniques (single-molecule tracking, 3D FISH) to study transcription factor mobility and chromatin interactions. Proposes biophysical models where protein diffusion in the nucleus is guided by DNA/chromatin networks. Technological Innovations: Pioneered methods for single-molecule tracking and super-resolution imaging, enabling nanoscale and millisecond-resolution analysis of nuclear processes. Collaborates with experts in biophysics, chemistry, and imaging to integrate multidisciplinary approaches. Scientific Awards: Edward E. Penhoet Distinguished Endowed Chair (Global Health and Infectious Disease) Nature Structural & Molecular Biology – Selected Article of the Month (2007) His lab (http://tjian-darzacq.mcb.berkeley.edu/) explores how nuclear architecture influences gene expression, particularly in wound healing contexts. Future work aims to leverage advancements in microscopy and genome editing to unravel transcriptional rules in living organisms.

Banu İYİSANView profile

Associate Professor

• Nanobiotechnology
• Nanobiomaterials
• Polymers
• +8 more

Banu İyisan is an Associate Professor at Boğaziçi University's Institute of Biomedical Engineering, where she founded and leads the Biofunctional Nanomaterials Design Laboratory (BIND Lab). Her research group became a Max Planck Partner Group in 2023 through collaboration with the Max Planck Institute for Polymer Research. She holds a PhD in Chemistry from Technical University of Dresden (2016), an MSc in Chemical Engineering from Istanbul Technical University (2011), and a BSc in Chemical Engineering from the same institution (2009), including an Erasmus study period at Technical University of Munich. Her multidisciplinary research integrates nanobiotechnology, polymer science, and biomaterials engineering to develop advanced nanocarriers for biomedical applications. Primary focus areas include: Design of stimuli-responsive nanocapsules for targeted drug delivery Development of multimodal nanoparticles for cancer theranostics Protein-nanoparticle interactions and their impact on therapeutic efficacy Light-activated nanotherapeutic systems Hybrid polymer-lipid nanostructures for enhanced drug encapsulation Her publication portfolio demonstrates consistent focus on advanced nanocarrier systems for biomedical applications, with recent work emphasizing multimodal functionality, smart drug release mechanisms, and clinical translation of nanotechnologies. Trends show increasing complexity in nanocarrier design and expanded applications in oncology and diagnostic imaging. Awards and recognition include: Max Planck Partner Group leadership (2023) She leads several major research initiatives as Principal Investigator: Light-Driven Multimodal Nanocarriers (Max Planck Partnership, 2023-2028) Smart Biopolymer-Coated Gold Nanorods (YÖK ADEP, 2025-2027) Smart Nanocapsules for Breast Cancer Therapy (TUBITAK 2247, 2022-2025) Multimodal Polymersomes for Image-Guided Delivery (TUBITAK-DAAD, 2025-2027) The BIND Lab conducts experimental research in functional nanomaterials, focusing on synthesis, characterization, and biomedical validation of nanocarriers. Current work involves collaborations on magnetic particle imaging systems and photothermal therapy platforms.

Iredia IyamuView profile

Assistant Professor

• Chemical Probes
• Epigenetics
• Drug Discovery
• +4 more

Iredia Iyamu is an Assistant Professor in the Department of Medicinal Chemistry at the University of Kansas School of Pharmacy. She directs research focused on developing chemical probes for disease targets with applications in drug discovery and target validation. Education: PhD in Chemistry, Northeastern University (2016) MSc in Analytical and Environmental Chemistry, University of Benin (2009) BSc in Industrial Chemistry, Ambrose Alli University (2004) Research Focus: Her laboratory develops chemical probes for disease targets using high-throughput screening and fragment-based lead discovery. Research areas include nicotinamide N-methyltransferase (NNMT) inhibitors, protein arginine methyltransferase inhibitors, and TRIP8b-HCN interaction modulators. Current projects explore bisubstrate inhibitors for improved selectivity in epigenetic regulation. Publication Trends: Recent articles demonstrate expertise in enzyme inhibitor design with emphasis on structure-activity relationships, chemoproteomic validation, and cell-potent chemical probes. Work frequently appears in medicinal chemistry and biochemistry journals.

Philip RomeroView profile

Associate Professor

• Protein Engineering
• Computational Biology
• Machine Learning
• +3 more

Philip Romero, Ph.D., is an Associate Professor in the Department of Biomedical Engineering at Duke University. He earned his doctorate from the California Institute of Technology in 2012 and leads the Romero Lab, which relocated to Duke in 2023. His research focuses on developing computational and experimental methods for protein engineering, with applications spanning therapeutics, biocatalysis, and synthetic biology. Research Interests: Romero's work integrates machine learning, microfluidics, and high-throughput experimentation to study protein fitness landscapes. Key areas include: Self-driving laboratories for autonomous protein optimization Neural network models for predicting protein functions Therapeutic enzyme engineering (ACE2, caspases, lysins) Microfluidic platforms for deep mutational scanning His recent publications demonstrate a strong emphasis on machine learning-guided protein design, with 80% of post-2022 publications involving AI/ML methods. Therapeutic applications against infectious diseases (particularly SARS-CoV-2) and microbiome engineering represent emerging directions. Lab & Advising: The Romero Lab develops novel technologies for protein engineering, including custom gene library assembly platforms and droplet microfluidics systems. Romero mentors graduate students (e.g., Nishit, who recently defended a thesis on transcription factor engineering) and has collaborated with researchers across computational biology, metabolic engineering, and virology.

• Biocatalysis
• Fungal Enzymes
• Bacterial and Algal Polymers
• +2 more

Anna Jarosz-Wilkołazka , Professor of Biological Sciences at the Maria Curie-Skłodowska University (UMCS) in Lublin, is affiliated with the Faculty of Biology and Biotechnology and leads research at the Department of Biochemistry and Biotechnology . With expertise spanning fungal enzymes, microbial polymers, and biomaterial modification, her work bridges biochemistry, biotechnology, and environmental science. Current research focuses on biocatalysis in aqueous/non-aqueous systems , fungal enzyme applications (particularly laccases), and the characterization of extracellular polymeric substances (EPS) from bacteria and algae for biosorption and bioflocculation. She has coordinated major research projects including "Modification of biopolymer materials with protease inhibitors" (NCN OPUS 13, 2017-2022) and "Oxalate oxidase in Abortiporus biennis" (NCN Opus 5, 2015-2019). Her recent publications (2016-2023) highlight advancements in fungal laccase immobilization for pollutant removal, EPS applications for heavy metal biosorption, and novel bioactive dyes. A 2023 study investigated oxalate oxidase sources in wood-rotting fungi, while 2020 work explored EPS from endophytic Fusarium culmorum strains affecting cereal crops. Earlier studies focused on lignin degradation mechanisms (2017) and EPS-driven biomineralization (2016). As a scientific supervisor, she has guided NCN projects on Rhodococcus opacus EPS properties (2016-2021) and fungal enzyme immobilization techniques (2015-2018). She actively participates in science outreach through initiatives like the Mobile Science Festival and Design Thinking Week under Erasmus+.